secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001437749-26-000938
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Maria Sainz to Board of Directors and Audit Committee
--------------------------------------------------------------------------------

- Maria Sainz elected to Pulse Biosciences Board and Audit Committee effective January 8, 2026.
- Sainz brings over 30 years of healthtech experience; currently CEO of Hyperfine, Inc. (NASDAQ: HYPR).
- Initial stock option grant of 50,000 shares; annual retainer of $55,000 plus $13,000 for Audit Committee.
- Previously CEO of Concentric Medical, Aegea Medical, CardioKinetix; leadership at Guidant and Boston Scientific.
- Serves on boards of Shockwave Medical (SWAV), Spectranetics (SPNC), Avanos (AVNS), Orthofix (OFIX).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926000938/0001437749-26-000938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926000938/plse20260106_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-000938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer